| MMM |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$2.29 vs. cons $2.24 |
MEDIUM |
| MMM |
Report |
Q2 2026 adjusted organic sales growth |
BEAT |
pred ~3.4% vs. cons 3.15% |
MEDIUM |
| MMM |
Report |
Q2 2026 adjusted operating margin |
IN-LINE |
pred ~24.8% vs. cons 24.65% |
MEDIUM |
| MMM |
Guide |
Adjusted EPS guidance |
UNCHANGED |
guide ~$8.70 midpoint vs. cons $8.70 (FY2026) |
MEDIUM |
| MMM |
Guide |
Adjusted organic sales growth guidance |
LOWER |
guide ~3.0% vs. cons 3.1% (FY2026) |
MEDIUM |
| MMM |
Guide |
Adjusted operating-margin expansion guidance |
BETTER |
guide ~85 bps midpoint vs. cons 80 bps (FY2026) |
LOW |
| MMM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| MMM |
Return |
5-day cumulative residual |
+0.4% (FADE) |
The predicted Q2 EPS beat of ~$0.05 ($2.29 vs. $2.24) is absorbed by FY2026 guidance of ~$8.70 vs. consensus $8.70, implying second-half EPS of ~$4.27 vs. the pre-report implied ~$4.32. That ~$0.05 out-period cut should limit revisions and cause the initial organic-growth and margin relief rally to fade. |
MEDIUM |